as of 03-13-2026 3:46pm EST
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 965.6M | IPO Year: | 2021 |
| Target Price: | $10.43 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | 100.00 |
| 52 Week Low/High: | $3.81 - $10.08 | Next Earning Date: | 05-18-2026 |
| Revenue: | $49,590,000 | Revenue Growth: | 142.67% |
| Revenue Growth (this year): | 28.65% | Revenue Growth (next year): | 18.33% |
| P/E Ratio: | -87.86 | Index: | N/A |
| Free Cash Flow: | 27.5M | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See Remarks
Avg Cost/Share
$6.65
Shares
16,667
Total Value
$104,085.74
Owned After
1,226,507
See Remarks
Avg Cost/Share
$7.45
Shares
16,667
Total Value
$124,147.48
Owned After
1,226,507
SEC Form 4
See Remarks
Avg Cost/Share
$8.00
Shares
15,000
Total Value
$120,000.00
Owned After
1,685,426
SEC Form 4
See Remarks
Avg Cost/Share
$7.08
Shares
24,907
Total Value
$176,256.88
Owned After
2,705,346
SEC Form 4
See Remarks
Avg Cost/Share
$7.43
Shares
16,667
Total Value
$123,775.81
Owned After
1,226,507
SEC Form 4
Director
Avg Cost/Share
$7.22
Shares
135,400
Total Value
$977,019.32
Owned After
698,083
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hecht Beth | XERS | See Remarks | Mar 2, 2026 | Sell | $6.65 | 16,667 | $104,085.74 | 1,226,507 | |
| Hecht Beth | XERS | See Remarks | Feb 2, 2026 | Sell | $7.45 | 16,667 | $124,147.48 | 1,226,507 | |
| McCulloch Kevin | XERS | See Remarks | Jan 8, 2026 | Sell | $8.00 | 15,000 | $120,000.00 | 1,685,426 | |
| Shannon John Patrick Jr | XERS | See Remarks | Jan 5, 2026 | Sell | $7.08 | 24,907 | $176,256.88 | 2,705,346 | |
| Hecht Beth | XERS | See Remarks | Jan 2, 2026 | Sell | $7.43 | 16,667 | $123,775.81 | 1,226,507 | |
| JOHNSON JOHN | XERS | Director | Dec 19, 2025 | Sell | $7.22 | 135,400 | $977,019.32 | 698,083 |
SEC 8-K filings with transcript text
Mar 2, 2026 · 100% conf.
1D
+0.73%
$6.06
Act: -1.33%
5D
+13.02%
$6.80
Act: -7.06%
20D
+13.42%
$6.83
xers-20260302☐000186709600018670962026-03-022026-03-02
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 2, 2026
(Exact name of registrant as specified in its charter)
Delaware001-4088087-1082097 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 (Address of principal executive offices, including zip code)
(844) 445-5704 (Registrant's telephone number, including area code)
(Not applicable) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per shareXERSThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 2, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and twelve months ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number Description 99.1Press release, dated March 2, 2026, regarding the Company's fourth quarter and full year 2025 financial results
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 2, 2026Xeris Biopharma Holdings, Inc.
By:/s/ Steven M. Pieper Name: Steven M. Pieper Title: Chief Financial Officer
Jan 8, 2026 · 100% conf.
1D
+0.73%
$6.06
Act: -1.33%
5D
+13.02%
$6.80
Act: -7.06%
20D
+13.42%
$6.83
xers-20260108☐000186709600018670962026-01-082026-01-08
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2026
(Exact name of registrant as specified in its charter)
Delaware001-4088087-1082097 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 (Address of principal executive offices, including zip code)
(844) 445-5704 (Registrant's telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per shareXERSThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On January 8, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release announcing certain of its financial preliminary results for the fourth quarter and full year ended December 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information disclosed pursuant to Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit NumberDescription 99.1Press release issued by the Company dated January 8, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 8, 2026Xeris Biopharma Holdings, Inc.
By:/s/ Steven M. Pieper Name: Steven M. Pieper Title: Chief Financial Officer
Nov 6, 2025
xers-20251106☐000186709600018670962025-11-062025-11-06
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
(Exact name of registrant as specified in its charter)
Delaware001-4088087-1082097 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 (Address of principal executive offices, including zip code)
(844) 445-5704 (Registrant's telephone number, including area code)
(Not applicable) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per shareXERSThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and nine months ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number Description 99.1Press release, dated November 6, 2025, regarding the Company's third quarter financial results
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2025Xeris Biopharma Holdings, Inc.
By:/s/ Steven M. Pieper Name: Steven M. Pieper Title: Chief Financial Officer
See how XERS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "XERS Xeris Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.